US20150098952A1 - Novel therapeutic target and diagnostic marker for asthma and related conditions - Google Patents

Novel therapeutic target and diagnostic marker for asthma and related conditions Download PDF

Info

Publication number
US20150098952A1
US20150098952A1 US14/566,737 US201414566737A US2015098952A1 US 20150098952 A1 US20150098952 A1 US 20150098952A1 US 201414566737 A US201414566737 A US 201414566737A US 2015098952 A1 US2015098952 A1 US 2015098952A1
Authority
US
United States
Prior art keywords
allergic
expression
agent
antibody
asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/566,737
Other languages
English (en)
Inventor
Francesca Levi-Schaffer
Ido Bachelet
Ariel Munitz
Marc E. Rothenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Cincinnati Childrens Hospital Medical Center
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem, Cincinnati Childrens Hospital Medical Center filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Priority to US14/566,737 priority Critical patent/US20150098952A1/en
Assigned to CHILDREN'S HOSPITAL MEDICAL CENTER, D/B/A/ CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER reassignment CHILDREN'S HOSPITAL MEDICAL CENTER, D/B/A/ CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROTHENBERG, MARC E.
Assigned to YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM reassignment YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MUNITZ, ARIEL, BACHELET, IDO, LEVI-SCHAFFER, FRANCESCA
Publication of US20150098952A1 publication Critical patent/US20150098952A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/14—Disorders of ear, nose or throat
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/162—Conjunctival disorders, e.g. conjunctivitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Definitions

  • the present invention relates generally to the field of allergic conditions.
  • the present invention is concerned with providing a marker for the diagnosis of allergic inflammation, particularly, allergic airway inflammation such as asthma and related conditions, as well as with agents for the treatment of said conditions.
  • Asthma is a chronic and complex inflammatory disease of the airways characterized by airflow obstruction, bronchial hyper-responsiveness (BHR) and airway inflammation. It is the most common chronic illness of childhood, with up to 20% of children affected in some Western countries. The incidence as well as the number of hospital admissions attributable to asthma continues to rise in both adults and children. Over the last decade the importance of airway inflammation in the disease process has been carefully investigated, and revealed that the asthmatic tissue is characterized by the accumulation of a large number of inflammatory cells (e.g.
  • Eosinophils are thought to be key effector cells in asthma by the release of basic granule proteins, membrane phospholipid metabolites and a variety of cytokines.
  • the eosinophil basic proteins have been found to be highly toxic in vitro to respiratory epithelial cells, at concentrations detected in biological fluid from patients with asthma.
  • eosinophils produce matrix metalloproteinase (MMP)-9, tissue inhibitor of matrix metalloproteinase (TIMP)-1/2, contain heparanase and are a source for vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF) and b-fibroblast growth factor (b-FGF), indicating their role in asthma-associated symptoms.
  • MMP matrix metalloproteinase
  • TMP tissue inhibitor of matrix metalloproteinase
  • VEGF vascular endothelial growth factor
  • PDGF platelet derived growth factor
  • b-FGF b-fibroblast growth factor
  • eosinophils Since a central question concerning eosinophils is to understand the mechanisms by which these cells get activated or inhibited and whether a “disease-specific” activator exists, the inventors screened eosinophils with monoclonal antibodies (mAbs) produced to recognize epitopes expressed on T lymphocytes and NK cells, preferably. The inventors found that human eosinophils express 2B4 [Munitz, A. et al. (2005) J. Immunol. 174: 110-118], and that 2B4 is a functional activator receptor on these cells in vitro, suggesting that a complex network of activating signals regulate the immunological or inflammatory responses coordinated by eosinophils.
  • mAbs monoclonal antibodies
  • CD48 is a glycosyl-phosphatidyl-inositol (GPI) anchored protein belonging to the CD2-subfamily, which is involved in lymphocyte adhesion, activation and co-stimulation. It is expressed mainly on hematopoietic cells and exists in both a membrane-associated and a soluble form. Studies on CD48-deficient mice indicate that CD48 has a broad immunological importance. In fact, CD48 has been described to interact with extracellular matrix components such as heparin sulfate, facilitate cell adhesion, innate responses to bacterial infection and graft rejection and provide co-stimulatory signals to T and B lymphocytes. Furthermore, CD48 has a distinctive role in orchestrating mast cell innate responses towards E. coli .
  • GPI glycosyl-phosphatidyl-inositol
  • CD48 is a low affinity ligand for CD2 but a high affinity ligand for 2B4 [Brown, M. H. et al. (1998) J. Exp. Med. 188(11):2083-90].
  • CD48-2B4 interactions can modulate T cell, B cell and NK cell functions and cross-talk.
  • the absence of functional 2B4-CD48 interactions impairs NK cell cytotoxic response and IFN- ⁇ release upon tumor target exposure.
  • activated NK cells significantly increase the CD3-dependent proliferation of CD8 + and CD4 + T cells by a 2B4-CD48 dependent mechanism.
  • cross-linking of CD48 on the surface of rodent T lymphocytes induced mobilization of the intracellular calcium inositol triphosphate concentration.
  • T cell activation via CD48 combined with CD3 induced enhanced IL-2 release, T cell receptor signaling and cytoskeletal reorganization.
  • cross-linking of CD48 on the surface of rat or murine B cells induced strong homotypic adhesion suggesting that this molecule can be involved in B cell activation.
  • cross-linking of CD48 on purified tonsillar B cells significantly increased CD40-mediated activation.
  • CD48, in combination with IL-4 and/or IL-10 is able to induce B cell aggregation, proliferation and IgG secretion [Klyushnenkova, E. N. et al. (1996) Cell Immunol. 174(1):90-8].
  • the present invention show for the first time that CD48 is up regulated in two murine models of allergic eosinophilic airway inflammation. More particularly, the present invention demonstrates that CD48 is up-regulated in two mouse models of experimental asthma. The findings indicate that CD48 over-expression is at least partially regulated by IL-3.
  • the present invention provides CD48 as a molecular marker and as a target for therapeutic and diagnostic methods for allergic conditions, specifically, asthma and asthmatic related conditions.
  • Another object of the invention relates to a therapeutic composition for the treatment of allergic inflammation, particularly, allergic airway inflammation, using an anti-CD48 agent such as an anti-CD48 antibody, an antibody against a down-stream molecule of the CD48 stimulatory pathway, or a nucleic acid molecule specifically targeted to decrease CD48 expression or to decrease the expression of a down-stream member molecule of the CD48 stimulatory pathway.
  • an anti-CD48 agent such as an anti-CD48 antibody, an antibody against a down-stream molecule of the CD48 stimulatory pathway, or a nucleic acid molecule specifically targeted to decrease CD48 expression or to decrease the expression of a down-stream member molecule of the CD48 stimulatory pathway.
  • the invention provides a diagnostic method for detection of an allergic condition in a subject.
  • This method involves determining CD48 levels of expression by a suitable means either in the protein or nucleic acids level. Whereby elevated expression of CD48 in comparison to a negative control, indicates the presence of such condition.
  • the invention in a first aspect, relates to a method of treating an allergic condition, particularly, an allergic inflammation, specifically, airway inflammation such as asthma and nasal polyposis, atopic dermatitis, conjunctivitis and intestinal allergy.
  • This method comprises administering a therapeutically effective amount of an anti-CD48 agent which blocks CD48 stimulatory pathway, to a subject in need of such treatment.
  • the anti-CD48 agent used by the method of the invention preferably blocks CD48 stimulatory pathway by inhibiting the activity and/or the expression of CD48 or of a down-stream member molecule of the CD48 stimulatory pathway.
  • the anti-CD48 agent used by the invention may be a protein-based molecule, such as anti-CD48 antibody, which specifically binds to CD48.
  • the anti CD48 agent may also be an antagonist of the CD48 stimulatory pathway, capable of decreasing or blocking an agonist of said pathway, in a competitive or non-competitive manner.
  • the anti-CD48 agent may be a nucleic acid based molecule such as, antisense oligonucleotide specific to the CD48 sequence, a ribozyme having catalytic activity (such as cleavage) that renders the CD48 inactive, an interfering RNA (RNAi) such as small interfering RNA (siRNA), or a microRNA capable of preventing the expression (transcription and translation, respectively) of the CD48 into protein.
  • RNAi interfering RNA
  • siRNA small interfering RNA
  • microRNA capable of preventing the expression (transcription and translation, respectively) of the CD48 into protein.
  • the invention further provides a method of inhibiting the activity and/or expression of CD48 in cells of a subject in need thereof.
  • This method comprises the step of in vivo contacting the cells with an effective amount of an anti-CD48 agent.
  • the invention relates to a method for the diagnosis of an allergic condition in a subject.
  • the diagnostic method of the invention comprises the steps of: (a) obtaining a biological sample from said subject; and (b) determining the level of expression of CD48 in said biological sample by a protein-based or a nucleic acid-based detection method. It should be appreciated that elevated expression of CD48, in comparison with negative control, indicates the presence of an allergic condition.
  • the CD48 expression may be detected by a protein-based method comprising the steps of: (i) contacting the examined sample with a CD48 binding agent, preferably, an anti-CD48 antibody; and (ii) measuring the level of binding of the agent to the CD48 protein in the sample by a suitable protein based detection assay.
  • a suitable protein based detection assay may be immunohistochemical staining, Western blot analysis, immunopercipitation, flow cytometry, ELISA, competition assay, any combination thereof or any other suitable assay.
  • the CD48 expression may be detected by a nucleic acid based detection method such as in-situ hybridization, RT-PCR, nucleic acid based ELISA, RNAse protection assay, Northern blot analysis, any combination thereof or any other nucleic-acid based suitable assay.
  • a nucleic acid based detection method such as in-situ hybridization, RT-PCR, nucleic acid based ELISA, RNAse protection assay, Northern blot analysis, any combination thereof or any other nucleic-acid based suitable assay.
  • the invention relates to a kit for the diagnosis of an allergic condition, the kit comprising as follows: an agent for determining the presence of an analyte of interest, wherein said analyte of interest is one of CD48 protein or CD48 mRNA.
  • the kit further comprises calibration means.
  • FIG. 1A-1C DNA Microarray Analysis Identifies CD48 as an Allergen-Induced Gene in Allergic Eosinophilic Airway Inflammation
  • CD48 in Ovalbumin (OVA) A and A. fumigatus -challenged mice (B) as measured by gene chip analysis is shown.
  • the induction of CD48 in allergen-challenged mice as measured by Northern blot analysis is shown (C). Total RNA was electrophoresed, transferred and hybridized with a radiolabeled sequence-confirmed CD48 cDNA probe. The location of 18S RNA is shown. Each lane represents an extract from one separate mouse.
  • FIG. 2A-2B Peripheral Blood Eosinophils and Nasal Polyp Eosinophils of Atopic Asthmatics Display Enhanced Levels of CD48 Expression
  • the cells were additionally stained with rat anti-mouse CCR3 PE.
  • CCR 3+ /SSC high cells were identified as eosinophils and analyzed for CD48 expression. Data are presented as mean fluorescent intensity (MFI), each dot represents one donor.
  • FIG. 3A-B The Expression of CD48 on Human Peripheral Blood Eosinophils is Regulated by IL-3
  • FIG. 4A-E CD48 Expression is Independent of STAT6, IL-4 and IL-13
  • RNA was extracted from the lungs of wild-type (A-D, left panel), STAT6 deficient [A-B, right panel], IL-13 and IL-4/IL-13 deficient mice (C-D, middle and right panels respectively). Mice that express a tetracycline-inducible IL-13 were fed doxycycline-containing food for the indicated time periods (E). For all Northern blot assays, total RNA was electrophoresed, transferred and hybridized with a radiolabeled sequence confirmed CD48 cDNA probe. The location of 18S RNA is shown. Each lane represents an extract from one separate mouse, EtBr ethidium bromide.
  • FIG. 5 CD48 Activates Human Peripheral Blood Eosinophils to Release EPO (Eosinophil Peroxidase)
  • FIG. 6A-G IL-3 Regulates CD48 Expression In Vivo
  • IL-3 mixed with anti-IL-3 mAb at a 2:1 molar ratio, [IL-3C] was administered intranasal (A-D) or systemically (E-F) every other day for 21 days to normal BALB/c mice. Twenty-four hours after the last IL-3C administration, mice were sacrificed, BALF was performed and lungs and spleen excised for differential cell counts as assessed by FACS analysis (A-B, E). For assessment of CD48 expression (C-D, F), BALF and lung cells were stained additionally with anti-CD48 mAb and evaluated by FACS. Eosinophils from the spleen of IL-5 transgenic or wild type mice (G) were stained with anti-CD48 mAb and evaluated by FACS. For (A-B,E) data are presented as total cell number ⁇ SD; for (C-D and E-F) data are presented as mean fluorescence intensity [MFI] ⁇ SD, from 4-6 mice per group.
  • MFI mean fluorescence intensity
  • FIG. 7A-B CD48 is Upregulated on Murine Eosinophils in Experimental Asthma and in Allergic Peritonitis
  • OVA/alum sensitized mice were challenged with OVA. Mice were sacrificed at the indicated time points after the last allergen challenge and BALF (A) or peritoneal lavage (B) was performed. The cells were stained with PE-labeled anti-CD48 and FITC-labeled anti-CCR3. CCR3+/SSC high cells were gated and analyzed for CD48 expression. Data are expressed as mean fluorescence intensity [MFI] ⁇ SD from 4-6 mice per group.
  • FIG. 8A-C Neutralization of IL-3 in Murine Experimental Asthma Reduces CD48 Expression
  • OVA/alum sensitized mice were treated with anti-IL-3 mAb or an isotype-matched control mAb (2 mg/mouse) on day 23 (24 hrs before allergen challenge) and days 24 and 27 (1 hr before allergen challenge).
  • BALF was performed and lungs were excised, 24 hrs after the last allergen challenge.
  • BALF cells were stained with PE-labeled anti-CD48 and FITC-labeled anti-CCR3.
  • CCR3+/SSC high cells were gated and analyzed for CD48 expression (A) and percentage of eosinophils, defined as CCR3+/SSC high cells (B). Lungs were fixed, paraffin embedded, stained for H&E and scored as described (C).
  • a and B data are expressed as mean fluorescence intensity [MFI] ⁇ SD or percentage of cells, respectively.
  • C data are expressed as mean inflammatory score ⁇ SD. All data were obtained from 4-6 mice per group.
  • n 3*, p ⁇ 0.05.
  • FIG. 9 Cellular Source of CD48, CD2 and 2B4 in the Lungs
  • FIG. 10A-G Neutralization of CD48 Attenuates Eosinophilic Inflammation, Th2 and Proinflammatory Cytokines Expression in the BALF
  • OVA/alum sensitized mice were treated with anti-CD48, anti-CD2 or anti-2B4 mAbs or control antibodies (Rat IgG, Hamster IgG) on day 23 and days 24 and 27 one hour before allergen challenge (250 ⁇ g per mice). Twenty four hours after the last allergen challenge BALF was performed and the cells were stained for differential cell identification. CCR3+/VLA4+/CD3 ⁇ /SSC high high cells were gated and considered as eosinophils (A). Assessment of IL-4, IL-5, IL-13, TNF- ⁇ , eotaxin-1 (B-F respectively) in the BALF was detected by ELISA according to the manufacturers' instructions.
  • mice/group/n mice/group/n.
  • FIG. 11A-D Neutralization of CD48 Attenuates Lung Inflammation
  • mice were sensitized, challenged and treated as described.
  • the lung tissue was fixed, paraffin embedded and stained with H&E for assessment of inflammation.
  • Quantitative analysis of alveolar space (B), peribronchial inflammation (C) and lung perivascular (D) is presented.
  • FIG. 12A-C Neutralization of CD48 Attenuates Goblet Cell Hyperplasia, Mucus Production and Smooth Muscle Thickening in the Lung.
  • mice were sensitized, challenged and treated as described.
  • the lung tissue was fixed, paraffin-embedded and stained with PAS for assessment of goblet cell hyperplasia and mucus production.
  • the present study is the first demonstration (both in humans and mice) that CD48 is expressed in eosinophils and its expression is directly correlated with the triggering of the asthmatic response, as detailed below. Furthermore, it is also the first report implicating CD48 in allergy, and the allergic response.
  • the present invention provides a method of treating an allergic condition, specifically, allergic airway inflammation such as asthma or nasal polyposis, atopic dermatitis, conjunctivitis and intestinal allergy.
  • the method of the invention comprises administering a therapeutically effective amount of an anti-CD48 agent that blocks CD48 stimulatory pathway, to a subject in need of said treatment.
  • said anti-CD48 agent is an anti-CD48 antibody.
  • the present invention provides a method of inhibiting the activity and/or expression of CD48 in cells of a subject suffering from an allergic condition, wherein said method comprises in vivo contacting said cells with an effective amount of an anti-CD48 agent.
  • the invention further encompasses ex vivo contacting said cells with the anti-CD48 agent.
  • the present invention relates to a method for the treatment of allergic conditions such as asthma, atopic dermatitis, conjunctivitis, intestinal allergy, and nasal polyposis, through abrogating, inhibiting or decreasing CD48 expression, or through eliminating, reducing or neutralizing CD48 activity.
  • Such treatment comprises administering a therapeutically effective amount of an anti-CD48 agent to a subject in need.
  • anti-CD48 agent or “an agent that blocks CD48 stimulatory pathway” refers to any compound, complex or composition which reduces, or even abrogates, the physiological phenomena which are caused by, or are downstream from CD48 activation. More particularly, such agent reduces or even inhibits the stimulatory signaling by other member molecules which are down-stream from the CD48 molecule, in such pathway which is involved in the allergic inflammatory condition. Said agent may be effective at various levels: firstly at the mRNA expression level, where CD48 (or any other down-stream member molecule) expression may be reduced (or inhibited) by inhibiting its transcripts e.g. through specific antisense oligonucleotides or by various modes of interfering RNAs, such as RNAi, siRNA, microRNA and ribozyme, which more directly interfere with translation.
  • Antisense oligonucleotides refer to a nucleotide comprising essentially a reverse complementary sequence to a sequence of CD48 mRNA.
  • the nucleotide is preferably an oligodeoxynucleotide, but also ribonucleotides or nucleotide analogues, or mixtures thereof, are contemplated by the invention.
  • the antisense oligonucleotide may be modified in order to enhance the nuclease resistance thereof, to improve its membrane crossing capability, or both.
  • the antisense oligonucleotide may be linear, or may comprise a secondary structure. It may also comprise enzymatic activity, such as ribozyme activity.
  • ribozyme it is meant an RNA molecule which has complementarity in a target binding region to a specified gene target, for example CD48, and also has an enzymatic activity which is active to specifically cleave target RNA. Said molecule is capable of catalyzing a series of reactions including the hydrolysis of phosphodiester bonds in trans (and thus can cleave other RNA molecules) under physiological conditions. Such enzymatic nucleic acid molecules can be targeted to virtually any RNA transcript, and achieve efficient cleavage in vitro. That is, the enzymatic RNA molecule is able to intermolecularly cleave RNA and thereby inactivate a target RNA molecule.
  • the complementary regions allow sufficient hybridization of the enzymatic RNA molecule to the target RNA and which ensures specific cleavage.
  • One hundred percent complementarity is preferred, but complementarity as low as 50-75% may also be useful in this invention.
  • the nucleic acids may be modified at the base, sugar, and/or phosphate groups.
  • RNA interference refers to the silencing or decreasing of gene expression by siRNAs. It is the process of sequence-specific, post-transcriptional sequence-specific gene silencing in animals and plants, initiated by siRNA that is homologous in its duplex region to the sequence of the gene to be silenced, particularly CD48. The expression of the gene is either completely or partially inhibited. RNAi may also inhibit the function of a CD48 RNA, and said function may be completely or partially inhibited.
  • miRNA single-stranded RNA molecules of about 21-23 nucleotides in length thought to regulate the expression of other genes. miRNAs are encoded by genes that are transcribed from DNA but not translated into protein (non-coding RNA), instead they are processed from primary transcripts known as pri-miRNA to short stem-loop structures called pre-miRNA and finally to functional miRNA. Mature miRNA molecules are complementary to regions in one or more messenger RNA (mRNA) molecules, which they target for degradation.
  • mRNA messenger RNA
  • CD48 activity may be reduced through the use of an antagonist of the receptor, a partial antagonist or an antibody that either competes with the natural agonist, blocks the activity or encourages the uptake of the CD48 molecule.
  • the anti-CD48 agent may thus be a nucleic acid sequence, a protein, a peptide, an antibody or a small organic molecule.
  • a preferred anti-CD48 agent is an anti-CD48 antibody, but other agents may be effective as well, such as CD48-specific siRNA, RNAi, microRNA and Ribozyme.
  • CD48 inhibitors and/or antagonists include anti-CD48 specific antibody fragments (F(ab′)2 or Fab′), single chain Fv, and Fc-fusion protein of CD48 ligands, e.g. Fc fusion proteins of 2B4 or CD2.
  • the anti-CD48 antibody used in the method of treatment may be of polyclonal or monoclonal origin.
  • a monoclonal antibody may be improved, through a humanization process, to overcome incompatibility problems. Rapid new strategies have been developed recently for antibody humanization which may be applied for such antibody. These technologies maintain the affinity, and retain the antigen and epitope specificity of the original antibody [Rader, C., et al. (1998) Proc. Natl. Acad. Sci. USA. 95: 8910-8915; Mateo, C. et al. (1997) Immunothechnology 3: 71-81].
  • a “humanized” antibody in which, for example animal (say murine) variable regions are fused to human constant regions, or in which murine complementarity-determining regions are grafted onto a human antibody. Unlike, for example, animal-derived antibodies, “humanized” antibodies often do not undergo an undesirable reaction with the immune system of the subject.
  • humanized and its derivatives refers to an antibody which includes any percent above zero and up to 100% of human antibody material, in an amount and composition sufficient to render such an antibody less likely to be immunogenic when administered to a human being. It is being understood that the term “humanized” reads also on human derived antibodies or on antibodies derived from non-human cells genetically engineered to include functional parts of the human immune system coding genes, which therefore produce antibodies which are fully human.
  • CD48 expression may be understood as the presence of CD48 protein or mRNA in the cells of interest, particularly leucocytes, more particularly eosinophils. It should be appreciated that the invention further encompasses the presence of CD48 in any body fluid sample and in any immune-system cell (particularly the Th2 associated cells).
  • CD48 The expression of CD48 was evaluated on human peripheral blood eosinophil after incubation with various cytokines and chemokines, among them IL-3, IL-5 and GM-CSF, which are eosinophil survival cytokines and chief regulators of eosinophil functions, including priming and activation [Giembycz, M. A. and Lindsay, M. A. (1999) Pharmacol. Rev. 51: 213-340]. These cytokines share a 13C-chain that is responsible for activating their signaling pathways and consequent effects.
  • cytokines and chemokines among them IL-3, IL-5 and GM-CSF, which are eosinophil survival cytokines and chief regulators of eosinophil functions, including priming and activation [Giembycz, M. A. and Lindsay, M. A. (1999) Pharmacol. Rev. 51: 213-340].
  • cytokines share a 13C-chain that is responsible
  • a further aspect of the present invention concerns a method for the diagnosis of an allergic condition and particularly of asthma and related conditions, said method comprising obtaining a biological sample from the examined subject and determining the level of expression of CD48 in the sample. Elevated expression of CD48, in comparison with negative control, indicates the presence of asthma or an asthma-related condition.
  • the biological sample may be a body fluid sample such as leucocyte-containing body fluid, blood, lymph, milk, urine, faeces, semen, appendix, spleen, extractstears, sputum, nasal, mucus, amniotic fluid, bronchoalveolar lavage, pleuric fluid, peritoneal fluid and tonsillar tissue extractstears, more preferably, a leucocyte-containing body fluid.
  • a body fluid sample such as leucocyte-containing body fluid, blood, lymph, milk, urine, faeces, semen, appendix, spleen, extractstears, sputum, nasal, mucus, amniotic fluid, bronchoalveolar lavage, pleuric fluid, peritoneal fluid and tonsillar tissue extractstears, more preferably, a leucocyte-containing body fluid.
  • the leucocyte-containing body fluid may be any body fluid, for example, blood, lymph, milk, urine, faeces, semen, appendix, spleen, extractstears, sputum, nasal, mucus, amniotic fluid, bronchoalveolar lavage, pleuric fluid, peritoneal fluid and tonsillar tissue extractstears.
  • Said diagnostic method of the invention may be applied at two levels.
  • CD48 is detected at the protein level, in which case said method comprises contacting a biological sample with a CD48 binding agent and measuring the level of binding of said agent to said CD48 protein, whereby elevated binding of CD48, in comparison with a negative control, indicates the presence of said allergic condition.
  • said CD48 binding agent is an anti-CD48 antibody.
  • Detection of CD48 at the protein level may be effected through various means, including the detection of CD48 in intact cells, as in e.g. FACS analysis, ELISA Spot Assay or immunohistochemistry, or through any methodology which involves cell lysis and protein detection, such as e.g. Western Blot, ELISA, RIA, etc. All these methodologies are well known to the man skilled in the art, and have been described, e.g., in Current Protocols in Immunology, Coligan et al. (eds), John Wiley & Sons. Inc., New York, N.Y., 1999.
  • antibody as used herein throughout this specification is meant to include intact molecules as well as fragments thereof, such as, for example, Fab and F(ab′)2, which are capable of binding antigen, in this case the CD48 molecule (or protein).
  • Such antibody fragments are within the scope of the present invention and may be used for the kits and the treatment and diagnostic methods disclosed herein for intact antibody molecules, to the extent where said fragments have the same biological activity, e g inhibition of CD48 function/expression, or recognition of the CD48 protein, as the intact antibody.
  • fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab′)2 fragments).
  • Said antibody may be of polyclonal or monoclonal antibody.
  • Methods of preparing polyclonal and monoclonal antibodies are well known to the man skilled in the art.
  • the biological sample used by the invention may be treated with a solid phase support or carrier such as nitrocellulose, or other solid support or carrier which is capable of immobilizing cells, cell particles or soluble proteins.
  • a solid phase support or carrier such as nitrocellulose, or other solid support or carrier which is capable of immobilizing cells, cell particles or soluble proteins.
  • the support or carrier may then be washed with suitable buffers followed by treatment with a detectably labeled antibody in accordance with the present invention, as noted above.
  • the solid phase support or carrier may then be washed with the buffer a second time to remove unbound antibody.
  • the amount of bound label on said solid support or carrier may then be detected by conventional means.
  • solid phase support By “solid phase support”, “solid phase carrier”, “solid support”, “solid carrier”, “support” or “carrier” is intended any support or carrier capable of binding antigen (CD48) or antibodies against CD48.
  • Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon amylases, natural and modified celluloses, polyacrylamides, and magnetite.
  • the nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention.
  • the support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody.
  • the support or carrier configuration may be spherical, as in a bead, cylindrical, as in the inside surface of a test tube, or the external surface of a rod.
  • the surface may be flat such as a sheet, test strip, etc.
  • Preferred supports or carriers include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody specific for CD48 or the CD48 antigen, or will be able to ascertain the same by use of routine experimentation.
  • binding activity of a given lot of antibody, of the invention as noted above may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.
  • an anti-CD48 antibody in accordance with the present invention can be detectably labeled is by linking the same to an enzyme and used in an enzyme immunoassay (EIA).
  • EIA enzyme immunoassay
  • This enzyme when later exposed to an appropriate substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or by visual means.
  • Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase.
  • the detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.
  • Detection may be accomplished using any of a variety of other immunoassays.
  • R-PTPase receptor tyrosine phosphatase
  • RIA radioimmunoassay
  • the radioactive isotope can be detected by such means as the use of a ⁇ counter or a scintillation counter or by autoradiography.
  • an antibody in accordance with the present invention with a fluorescent compound.
  • fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrine, pycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
  • the antibody can also be detectably labeled using fluorescence emitting metals such as 152 E, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriamine pentaacetic acid (ETPA).
  • fluorescence emitting metals such as 152 E, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriamine pentaacetic acid (ETPA).
  • the antibody can also be detectably labeled by coupling it to a chemiluminescent compound.
  • the presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
  • particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.
  • a bioluminescent compound may be used to label the anti-CD48 antibody used by the diagnostic method of the invention.
  • Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence.
  • Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.
  • An antibody molecule of the present invention may be adapted for utilization in an immunometric assay, also known as a “two-site” or “sandwich” assay.
  • an immunometric assay also known as a “two-site” or “sandwich” assay.
  • a quantity of unlabeled antibody (or fragment of antibody) is bound to a solid support or carrier and a quantity of detectably labeled soluble antibody is added to permit detection and/or quantitation of the ternary complex formed between solid-phase antibody, antigen, and labeled antibody.
  • Typical, and preferred, immunometric assays include “forward” assays in which the antibody bound to the solid phase is first contacted with the sample being tested to extract the antigen from the sample by formation of a binary solid phase antibody-antigen complex. After a suitable incubation period, the solid support or carrier is washed to remove the residue of the fluid sample, including unreacted antigen, if any, and then contacted with the solution containing an unknown quantity of labeled antibody (which functions as a “reporter molecule”). After a second incubation period to permit the labeled antibody to complex with the antigen bound to the solid support or carrier through the unlabeled antibody, the solid support or carrier is washed a second time to remove the unreacted labeled antibody.
  • a simultaneous assay involves a single incubation step as the antibody bound to the solid support or carrier and labeled antibody are both added to the sample being tested at the same time. After the incubation is completed, the solid support or carrier is washed to remove the residue of fluid sample and uncomplexed labeled antibody. The presence of labeled antibody associated with the solid support or carrier is then determined as it would be in a conventional “forward” sandwich assay.
  • stepwise addition first of a solution of labeled antibody to the fluid sample followed by the addition of unlabeled antibody bound to a solid support or carrier after a suitable incubation period is utilized. After a second incubation, the solid phase is washed in conventional fashion to free it of the residue of the sample being tested and the solution of unreacted labeled antibody. The determination of labeled antibody associated with a solid support or carrier is then determined as in the “simultaneous” and “forward” assays.
  • said diagnostic method is effected at the mRNA level, in which case said determination comprises measuring the level of CD48 mRNA expression by appropriate means, whereby elevated levels of CD48 mRNA, in comparison with a negative control, indicates the presence of an allergic condition, specifically, asthma.
  • Appropriate means for measuring mRNA levels include applying the methods of RT-PCR, PCR, Nucleic acid based ELISA and hybridization with a labeled probe, e.g. in Northern blot, or in situ hybridization. These are well known methods which are familiar to the man skilled in the art of molecular biology.
  • Nucleic acid based ELISA may be performed by coating ELISA plates with antisense nucleic acid sequence derived from CD48, incubating tagged or labeled RT-PCR products obtained from the examined sample with the plates and quantitating the bound nucleic acid sequence.
  • Tag's suitable for such purpose may be for example avidin/biotin, GFP, myc, FLAG and the like.
  • said determination comprises providing primers for specific amplification of CD48 transcripts, together with nucleotides and amplification reagents, providing conditions for allowing CD48 amplification, whereby elevated levels of CD48 amplification products, in comparison with a negative control, indicates the presence of at least one of asthma, allergy or an asthma- or allergy-related condition.
  • RT-PCR refers to a process of reverse transcription of mRNA into cDNA which is subsequently subjected to PCR reaction.
  • PCR Polymerase Chain Reaction
  • PCR involves amplifying one or more specific nucleic acid sequences by repeated rounds of synthesis and denaturing under appropriate conditions.
  • PCR requires two primers that are capable of hybridization with a single-strand of a double-stranded target nucleic acid sequence which is to be amplified under appropriate hybridization conditions.
  • this double-stranded target sequence is denatured and one primer is annealed to each single-strand of the denatured target.
  • the primers anneal to the target nucleic acid at sites removed (downstream or upstream) from one another and in orientations such that the extension product of one primer, when separated from its complement, can hybridize to the extension product generated from the other primer and target strand. Once a given primer hybridizes to the target sequence, the primer is extended by the action of a DNA polymerase.
  • DNA polymerase which is heat stable is generally utilized so that new polymerase need not be added after each denaturation step.
  • thermostable DNA polymerase is known to one of ordinary skill in the art, e.g. Taq polymerase.
  • the extension product is then denatured from the target sequence, and the process is repeated.
  • the primer extension or PCR product may be un-labeled.
  • the gel-banding pattern of the resulting fragments may be visualized by ethidium bromide (EtBr), or by silver staining.
  • the primer extension or PCR product may be body-labeled, by using labeled nucleotide during the PCR reaction.
  • label refers to any atom or molecule which can be used to provide a detectable (preferably quantifiable) signal, and which can be attached to a nucleic acid or protein. Labels may provide signals detectable by fluorescence, radioactivity, colorimetry, gravimetry, X-ray diffraction or absorption, magnetism, enzymatic activity, and the like.
  • nucleic acid refers to polymer of nucleotides, which may be either single- or double-stranded, which is a polynucleotide such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA).
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • the terms should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single-stranded (such as sense or antisense) and double-stranded polynucleotides.
  • DNA used herein also encompasses cDNA, i.e. complementary or copy DNA produced from an RNA template by the action of reverse transcriptase (RNA-dependent DNA polymerase).
  • results obtained through the herein described diagnostic methods are always compared to a reference value, obtained e.g. from a negative control, which assists the medical practitioner to arrive at the correct diagnosis, positive or negative.
  • CD48 expression on eosinophils was evaluated in a murine experimental asthma and allergic peritonitis.
  • the data obtained from the model presented herein demonstrate that CD48 expression increased in a time-dependent fashion after allergen challenge.
  • IL-3 neutralization in OVA-challenged mice reduced eosinophil CD48 expression, but not to the baseline level that is observed in saline-treated mice.
  • IL-3 is the only identified cytokine that up-regulates eosinophil CD48 expression, it is unlikely to be the only factor responsible for this phenomenon in vivo. It is possible that IL-3 and IL-4 act in concert to influence CD48 expression on various cell types. Alternatively, higher doses of anti-IL-3 may be required for a more dramatic effect.
  • CD48 together with IL-3 regulates the release of specific mediators that are beneficial to the host in helminth and bacterial infections (i.e. innate mechanisms) but unfavorable in allergic settings (i.e. adaptive mechanisms).
  • the inventors may hypothesize that compensatory mechanisms (yet to be defined) present in the lungs of allergen-challenged mice can upregulate CD48 in the absence of one single pathway. It should be noted that the possibility that CD48 is upregulated in the lungs of OVA-challenged mice due to local inflammation and recruitment of CD48-expressing cells, cannot be ruled out. Yet, upregulation of CD48 was unchanged in STAT-6, IL-4, IL-13 and eotaxin-1/IL-5 deficient mice, which fail to develop an eosinophil infiltrate (data not shown). Thus, upon allergen challenge lung expression of CD48 remains unaltered.
  • CD48 signaling cascade contributes to eosinophil activation and degranulation in asthma.
  • increased CD48 expression might shift the resting threshold of eosinophils toward activation.
  • CD48 can induce signal transduction as it binds Lck, Fyn and G proteins [Patel, V. P. et al. (2001) J. Immunol. 166: 754-64; Stefanova, I, et al. (1991) Science 254: 1016-9)].
  • Cross-linking of CD48 on purified tonsillar B cells significantly increased CD40-mediated activation [Klyushnenkova, E. N. et al. (1996) Cell Immunol. 174: 90-8], and cross-linking CD48 in combination with IL-4 and/or IL-10 is able to induce B cell aggregation, proliferation and IgG secretion. Therefore, the anti-CD48 agent used by the method of the invention may target other down-stream member molecules of the CD48 stimulatory pathway, such as Lck, Fyn and G proteins.
  • CD48 is upregulated on the single cell level by at least two mediators that are expressed in the asthmatic milieu: IL-3 and IL-4.
  • the abundance of pathways that regulate CD48 expression in vivo highlights CD48 importance.
  • CD48 deficient mice show considerable defects in CD4 + T cell activation.
  • the inhibitory effect of anti-CD48 treatment in our settings is likely to be only partially dependent on T cell co-stimulation via CD2, since anti-CD2 treated mice displayed a mild reduction of the disease parameters in comparison to anti-CD48 mAb treated mice. Supporting this finding is the observation that CD2 deficient mice do not display the same effects observed in CD48 deficient mice. This suggests a broader and more substantial role for CD48 in the immune system than recognized.
  • line of evidence supports a broad immunological role for CD48.
  • CD48 is up-regulated in experimental asthma indicates the role of this molecule in human disease as well.
  • CD48 was up-regulated both in human peripheral blood eosinophils and in human nasal polyp eosinophils of atopic asthmatics vs. normal controls. The latter finding is of great consideration since the most prevalent disease associated with nasal polyposis is bronchial asthma.
  • CD48 is herein presented as a new target for future therapeutic and diagnostic approaches.
  • asthma is an inflammatory condition of the bronchial airways, characterized by airflow obstruction and bronchial hyper-responsiveness, resulting in increased mucus production, mucosal swelling and muscle contraction. These changes produce airway obstruction, chest tightness, coughing and wheezing. When severe, this can cause severe shortness of breath and low blood oxygen.
  • asthmatic condition has various etiologies, including allergic manifestations in sensitized individuals (“allergic asthma”), asthma provoked by factors such as vigorous exercise, irritant particles, viral respiratory infections and/or psychological stress (“bronchial asthma” or “spasmodic asthma”), amongst others.
  • allergic asthma allergic manifestations in sensitized individuals
  • bronchial asthma or “spasmodic asthma”
  • Allergy may be defined as a reaction to foreign substances (allergens) by the immune system.
  • allergens include pollens, dust mite, molds, dander, and certain foods.
  • allergic conditions include hay fever (allergic rhinitis), asthma, allergic eyes (allergic conjunctivitis), allergic eczema, hives (urticaria), and allergic shock (also called anaphylaxis and anaphylactic shock).
  • conjunctivitis is an inflammation of the conjunctiva (the outermost layer of the eye and the inner surface of the eyelids), most commonly due to an allergic reaction or an infection (usually bacterial or viral).
  • Atopic dermatitis (AD) is a chronic, highly pruritic, eczematous skin disease that follows patients from early childhood into puberty and sometimes adulthood. Also referred to as eczematous dermatitis, the disease often has a remitting/flaring course, which may be exacerbated by social, environmental, and biological triggers.
  • said therapeutic effective amount, or dosage is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved.
  • Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. In general, dosage is calculated according to body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the anti-CD48 agent in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the anti-CD48 agent is administered in maintenance doses, once or more daily.
  • a localized administration of the anti-CD48 agent is specifically preferred.
  • Said agent may be delivered via intravenous (i.v.), intramuscular (i.m.), intraperitoneal (i.p.) injections, orally (in liquid form or prepared as dosage unit forms like capsules, pills, lozenges, etc.).
  • the anti-CD48 agent may also be delivered in a local manner, via transdermal delivery using patches, ointment or cream.
  • Other routes of administration are intranasal, intradermal, sub-lingual, and intrathecal, although systemic delivery may be also used.
  • Possible delivery devices include aerosol (inhalation), liposomal carriers, drops, ready-to-use syringes, pills and capsules, amongst others.
  • CD48 may serve as a multifaceted molecule that regulates several eosinophil effector functions in disease settings. For example, elevated levels of CD48 on eosinophils and basophils correlated with increased infiltration of these cells to the lung, BALF and spleen.
  • CD48 has been reported to function as an adhesion molecule [Yokoyama, S. D. et al. (1991) J. Immunol. 146: 2192-2200], and it can bind directly to heparin sulfate on the surface of epithelial cells [Ianelli, C. J. et al. (1998) J. Biol. Chem. 273: 23367-23375]. Consequently, CD48 may influence homing, transmigration, and tissue retention of eosinophils in allergic settings.
  • the present invention also provides the use of an anti-CD48 agent as a preventive vehicle for allergic conditions.
  • CD48 is one of the molecules at the top of the signaling cascade involving the allergic response (which triggers the asthma attack)
  • inhibiting CD48 function/expression is a way of preventing the asthmatic or allergic condition to take place.
  • Such a drug is certainly a leap forward in asthma and allergy drug development, in view, that asthmatic and/or allergic patients are usually treated with drugs that ease the symptoms, but are not spared from the agony of the attack.
  • a preventive drug is hence much in demand for this target population.
  • patient or “subject in need” it is meant any mammal who may be affected by the above-mentioned conditions, and to whom the treatment and diagnosis methods herein described is desired, including human, bovine, equine, canine, murine and feline subjects.
  • patient is a human.
  • CD48 has an important role in eosinophil activation in a variety of allergic conditions not previously described.
  • the present invention also provides a kit for the diagnosis of an allergic condition, specifically, asthma and related conditions, said kit comprising as follows:
  • an agent for determining the presence of an analyte of interest wherein said analyte is selected from the group consisting of: CD48 protein and CD48 mRNA; calibration means; and
  • said agent is an anti-CD48 antibody.
  • Said antibody may be conjugated to a detectable label or not.
  • a second antibody is also supplied by the kit of the invention, wherein said second antibody is conjugated to a detectable label, it is produced in a different species from the first antibody, and it is capable of detecting the first antibody.
  • said agent may be a CD48-specific probe, said probe being a oligonucleotide sequence complementary and specific to the CD48 mRNA sequence, labeled by any suitable means, e g immunofluorescence labeling, luminescence, radioisotopes, etc.
  • the detection of CD48 mRNA may be effectuated through amplification of said specific mRNA, in PCR or RT-PCR reactions, and in which case said agent is a CD48-specific primer (typically specific complementary oligonucleotides).
  • the detection per se may be performed e.g. using FACS analysis, wherein the sample is analyzed by FACS using the appropriate parameters and comparing to a negative control.
  • the cells obtained from the collected sample may be fixed onto a slide, and CD48 expression detected via anti-CD48 antibodies or labeled probes (in situ detection).
  • Yet another detection method which may be utilized involves protein or RNA extraction and analysis, via e.g. Western blot, ELISA, Northern blot or PCR. Any one of these alternatives is specified in the manual of instructions accompanying the kit, accordingly.
  • calibration means may be a sample of a negative control in order to give a yes/no binary answer.
  • the calibration may also comprise a full calibration curve in order to give a quantitative answer as regards the severity of the allergic reaction, or of the asthmatic condition.
  • said kit may optionally further comprise at least one of the following components: means for obtaining a blood sample, means for isolating leucocytes from the blood sample, and means for detecting the anti-CD48 antibody or CD48-specific probe.
  • the invention further provides a pharmaceutical composition for the treatment of an allergic condition comprising as an active ingredient a therapeutically effective amount of an anti-CD48 agent and optionally further comprising pharmaceutically acceptable carrier, diluent, excipients and/or additive.
  • FITC conjugated anti-CCR3 was obtained from R&D Systems (Minneapolis, Minn.).
  • Anti-CD3-APC, anti-VLA2-PE (DX5), anti-CD4-PE-Cy5, anti-rat-PE, anti-rat-FITC, streptavidin-PE and streptavidin-Cy 5 were all purchased from eBioscience, (San Diego, Calif.).
  • Anti-B220-APC, anti-CD2 and anti-CD48-PE were obtained from Biolegend (San Diego, Calif.).
  • Anti-2B4 mAb (a kind gift of Dr. Vinay Kumar, University of Chicago) and anti-CD2 were conjugated to biotin using a standard protocol.
  • mice were obtained from the National Cancer Institute (Frederick, Md.) or Harlan laboratories (Israel) and housed under specific pathogen-free conditions. Mice deficient in STAT6 or IL-4R ⁇ in the Balb/c background were obtained from Jackson Laboratories (Bar Harbor, Me.). IL-13-deficient mice and mice deficient in both IL-4 and IL-13 were kindly provided by Dr. Andrew McKenzie. Generation of eotaxin-deficient IL-5-transgenic mice was previously described [Mishra, A. et al. (1999) J. Clin. Invest. 103(12):1719-27].
  • mice 7-8 weeks old mice were obtained from Harlan Laboratories (Israel) and housed under specific pathogen-free conditions. Mice were sensitized by i.p. injection with 100 ⁇ g of OVA adsorbed onto 1 mg of aluminum hydroxide in 250 ⁇ l of saline on days 0 and 14. On days 24 and 27, the mice were lightly anesthetized with inhaled isofluorane and challenged intranasally with 50 ⁇ g of OVA or saline. The allergen challenge was performed by applying 50 ⁇ l of the same to the nostrils using a micropipette with the mouse held in a supine position. After instillation, the mice were held upright until alert.
  • mice were sacrificed by isofluorane inhalation at the indicated time points (0-24 hrs) following allergen challenge and BALF was performed for differential cell counts [Van Rijt, L. S. et al. (2004) J. Immunol. Meth. 288: 111-121].
  • lungs were excised, digested as described [Southam, D. S. et al. (2005) J. Allergy Clin. Immunol. 115: 95-102], and differential cell count performed.
  • anti-IL-3 (clone 8F8) (2 mg/mouse in 300 ⁇ l saline), anti-CD48, anti-CD2 (Biolegend, San Diego, Calif.), anti-2B4, or appropriate isotype matched controls (Hamster IgG and Rat IgG) were administered i.p on day 23 (24 hrs prior to allergen challenge) and on days 24 and 27 one hour prior to allergen challenge (250 ⁇ g/mouse in 300 ⁇ l saline). These concentrations were chosen because they had been previously shown to have a neutralizing effect in vivo. Mice were sacrificed 18 hrs after the last allergen challenge. BALF was performed for differential cell counts and eosinophils were assessed for CD48 expression.
  • lungs were excised, fixed in 4% paraformaldehyde, paraffin embedded and stained by H&E (hematoxylin/eosin). Calculation of total lung inflammation was performed by assessing alveolar space and perivascular and peribronchial infiltrate using the following key: O-no inflammation, 1-light inflammation, 2-moderate inflammation, and 3-severe inflammation.
  • mice 8-10 weeks old were sensitized subcutaneously on days 0 and 7 with 100 ⁇ g of OVA adsorbed onto 1.6 mg of aluminum hydroxide in 300 ⁇ l saline.
  • the mice were challenged i.p. with 3 ⁇ g of OVA in 200 ⁇ l of saline and sacrificed at the indicated time points (6 hrs-48 hrs). Thereafter, the peritoneal cavity was washed with 5 ml of Tyrode's gelatin buffer for differential cell counts.
  • mice were obtained as described [Finkelman, F. D. et al. (1993) J. Immunol. 151: 1235-1244].
  • IL-3 (Peprotech, Rocky Hill, N.J.) was administered intranasally or systemically in lightly anesthetized (isofluorane) BALB/c female mice (7-8 weeks old). Briefly, recombinant murine IL-3 (2-4 ⁇ g in 50 ⁇ l saline for intranasal administration and 8-10 ⁇ g in 100 ⁇ l saline) was delivered in conjunction with anti-IL-3 mAb (4-20 ⁇ g) (IL-3C).
  • IL-3C anti-IL-3 mAb
  • IL-3C IL-3/anti-IL-3 mAb complex
  • the mice received IL-3C every other day for 21 days. Mice were sacrificed 24 hrs after the last administration of IL-3C. Spleen, lung and BALF cells were assessed for CD48 expression by FACS (see below).
  • Total lung RNA (10-20 ⁇ g) was analyzed by electrophoresis in an agarose-formaldehyde gel, transferred to Gene Screen transfer membranes (NEN, Boston, Mass., USA) in 10 ⁇ SSC and cross-linked by UV radiation. Sequence confirmed probes were obtained from American Type Tissue Culture Collection (ATCC, Rockville, Md., USA) and labeled with 32 P using the Klenow reaction and random priming. Blots were hybridized under standard conditions.
  • Eosinophils were purified from peripheral blood of atopic asthmatics (see below) or age and sex matched normal individuals (blood eosinophil levels 5-10%) by MACS negative immunomagnetic separation as previously described [Munitz, A. et al. (2005) ibid. J. Immunol. 174: 110-118]. Asthmatic donors were all atopic individuals (total IgE>100 IU/ml blood) requiring intermittent gonist treatment (FEV1 values ranging from 75%.90% of normal). Non-asthmatic gender-matched controls were non-atopic and had FEV1 values greater than 95% of normal.
  • venous blood 50-100 ml was collected in heparinized syringes and left to sediment in 6% dextran (Amersham Biosciences, Uppsala, Sweden).
  • Leukocytes were centrifuged on Ficoll-Hypaque (density 1.077, Amersham Biosciences, Uppsala, Sweden), for 25 min, 700 g, 22° C.
  • Neutrophils and contaminating lymphocytes were tagged in the granulocyte-enriched pellet with micromagnetic beads bound to anti-CD16 and anti-CD3 antibodies (Miltenyi Biotech, GmbH, Bergisch Gladbach, Germany).
  • Eosinophils were purified by passing the cell suspension through a magnetic column (MACS).
  • Eosinophil preparations were re-suspended in medium containing RPMI-1640, 200 U/ml penicillin, 200 ⁇ g/ml streptomycin and 10% v/v heat inactivated FCS(RPMI 10%)
  • Asthmatic donors were all atopic individuals (total IgE>100 units) requiring intermittent ⁇ 2-agonist treatment (FEV 1 values ranging 75%-90% of normal FEV1).
  • Non asthmatic gender-matched controls were non-atopic and had FEV1 values greater than 95% of normal.
  • 96-well plates (Nunc, Roskilde, Denmark) were pre-coated with sheep anti-mouse IgG F(ab) (25 ⁇ g/ml) in PBS, for two hours, at 37° C., 5% CO 2 . Afterwards plates were washed three times with PBS and incubated with anti-CD48 mAb (Pharmingen, San Diego, Calif.) or an irrelevant isotype-matched control mAb (DAKO, Denmark) (1 ⁇ g/ml, 2 hrs at 37°, 5% CO 2 ) and washed three times.
  • Freshly isolated eosinophils were seeded in these pre-coated wells (2 ⁇ 105/200 ⁇ l) in RPMI-10% (as described above) and incubated for 30 min-18 hrs (37° C., 5% CO2). At the end of the incubation, cells were centrifuged (300 g, 5 min, 4° C.), supernatants collected, aliquoted, and stored at ⁇ 80° C. until assessed for EPO (eosinophil peroxidase) activity.
  • EPO eosinophil peroxidase
  • EPO Eosinophil Peroxidase
  • EPO release was determined by a colorimetric assay. Briefly, eosinophil culture supernatants (50 ⁇ l) were incubated (10-15 min, 37° C., 5% CO2) with a substrate solution that contained 0.1 mM O-phenylenediamine dihydrochloride in 0.05 M Tris buffer (pH 8.0), 0.1% Triton X-100 (37° C., 5% CO2) and 1 mM hydrogen peroxide (Merck, Darmstadt, Germany).
  • the reaction was stopped by the addition of 4 mM sulfuric acid (BDH, Dorset, UK) and the absorbance was determined at 492 nm in a spectrophotometer (PowerWaveTM XS, Bio-Tek Instruments, Bad Friedrichshall, Germany).
  • mice Total BALF cells (2 ⁇ 10 5 ) of treated mice were incubated with the aforementioned antibodies in a final volume of 100 ⁇ l of Hanks Balanced Salt Solution supplemented with 0.1% bovine serum albumin and 0.02% sodium azide for 30 min on ice.
  • Cell staining was performed by four-color flow cytometry using anti-CD3 APC, anti-c-kit Pe-Cy5, Anti-FccRI FITC, anti-CD4 Pe-Cy5, anti-CD48 PE (eBioscience, San Diego, Calif., USA), and anti-CCR3FITC (R&D, Systems, Minneapolis, Minn., USA). Thereafter, differential cell populations were electronically gated and assessed for expression of CD48, CD2 or 2B4.
  • differential cell populations were defined as follows: Eosinophils—SSC high , CCR high , CD49d high , c-kit low , Fc ⁇ RI low , Ly49b ⁇ and CD3 ⁇ ; Neutrophils-SSC high , CCR 3 ⁇ and CD3 ⁇ ; Lymphocytes—SSC low , CCR 3 ⁇ and either CD3 + or B220 + ; Mononcytes/macrophages—SSC high , FSC high , CCR3 ⁇ , CD3 ⁇ and FccRI ⁇ ; NK cells—SSC high , CCR3 ⁇ , DX5 + and CD3 ⁇ : NKT cells SSC low , CCR3 ⁇ , DX5 + and CD3 + .
  • the different cell types were identified through their surface antigens and physical parameters (SSC vs. FSC) as previously described [Van Rijt, L. S. et al. (2004) J. Immunol. Methods 288: 111-12]. For each staining at least ten thousand cells were collected and data analysis was performed using CellQuestTM software (Mansfield, Mass., USA).
  • Cytokines were measured with kits purchased from the following sources: IL-5; e-bioscience (San Diego, Calif.), IL-4 and IL-13; Biolegend (San Diego, Calif.), Eotaxin-2 and TNF- ⁇ ; R&D systems ((Minneapolis, Minn.). ELISA procedures were carried out according to the manufacturers' instructions. Lower detection limits for the various assays were: 7.8 pg/ml, 2 pg/ml, 16 pg/ml, 32 pg/ml and 16 pg/ml respectively. Assessment of RANTES, MCP-1 and MCP-5 was performed using the RayBio® cytokine protein Arrays (RayBiotech, Norcross, Ga., USA), according to manufacturer's instructions.
  • the number of PAS-positive and PAS-negative epithelial cells in individual bronchioles was counted. At least three medium-sized bronchioles (defined by having approximately 90.150 luminal airway epithelial cells) were counted per slide. Results are expressed as the percentage of PAS-positive cells per bronchiole, which is calculated from the number of PAS-positive epithelial cells per bronchus divided by the total number of epithelial cells of each bronchiole.
  • H&E stained slides were microphotographed and the mean pixel count of at least 10 different positions per bronchiole of each smooth muscle layer was obtained. This procedure was calculated from at least three medium-sized bronchioles per mouse.
  • RPMI-1640 supplemented with L-glutamine, heat-inactivated Fetal Calf Serum (FCS) and penicillin-streptomycin solutions were obtained from Biological Industries (Beit Haemek, Israel). All the chemicals used in this study were purchased from Sigma (Rehovot, Israel) and were of best available grade.
  • CD48 but not CD2 or 2B4 mRNA expression was significantly increased in both the OVA- and Aspergillus -induced allergic eosinophilic airway inflammation models ( FIG. 1A-B respectively.
  • OVA-induced experimental asthma model kinetic analysis revealed that CD48 mRNA was significantly up-regulated 18 hrs after the second allergen challenge but not after a single allergen challenge or 3 hrs after the second allergen challenge (not shown).
  • CD48 was up-regulated 18 hrs after the ninth allergen challenge. Subsequently, this data was confirmed by Northern Blot analysis. As shown in FIG. 1C there is a low basal expression of CD48 in the lungs of saline treated mice. However, the levels of CD48 were significantly up-regulated after OVA and Aspergillus challenge.
  • IL-2 IL-3, IL-4, IL-5, IL-8, IL-13, IFN- ⁇ , GM-CSF, SCF, TGF- ⁇ , eotaxin-1, RANTES and MIP-1 ⁇ that are found in the asthmatic milieu.
  • IL-3, IL-5 and GM-CSF share a common ⁇ chain ( ⁇ c) that transduces their signal, only IL-3 up-regulated CD48 expression ( FIG.
  • CD48 has an inducible expression pattern on eosinophils during induction of experimental asthma indicates that there is a factor in the asthmatic milieu that regulates this phenomenon. Asthma is a Th 2 associated process, therefore the inventors aimed to determine whether signaling pathways such as STAT6 or cytokines such as IL-4 and IL-13 that are key regulators of the asthmatic response are involved in the up-regulation of CD48. Therefore, OVA- and Aspergillus -induced experimental allergic-eosinophilic airway inflammation protocols were employed to STAT6-, IL-13- and IL-4/IL-13 deficient mice. Thereafter, total lung mRNA was extracted and subjected to Northern blot analysis. As shown in FIG. 4A-D , the up-regulation of CD48 expression was found to be independent of all of these factors in both the OVA- and Aspergillus -induced models.
  • inducible IL-13 transgenic mice display elevated levels of CD48 starting after 6 days of IL-13 induction, indicating that IL-13 over-expression is sufficient for CD48 overexpression ( FIG. 4E ).
  • CD48 Activates Human Eosinophils to Release EPO
  • CD48 on the eosinophil surface suggests that eosinophil responses may be regulated by this receptor.
  • Cross-linking of CD48 on human eosinophils induced EPO release ( FIG. 5 ).
  • CD48 cross-linking did not induce cytokine release, as IL-4, IL-8 and IFN- ⁇ were not detected in the culture supernatants.
  • cross-linking of CD48 in the presence of IL-3 did not enhance EPO release or cause cytokine release (data not shown).
  • IL-3 up-regulated CD48 expression in vivo in the mouse.
  • intravenous administration of IL-3C increased eosinophil and basophil numbers, as well as their CD48 expression in the spleen ( FIG. 6E-F ).
  • IL-3 is specifically responsible for CD48 up-regulation in vivo
  • the expression of CD48 was examined in eosinophils from IL-5 transgenic mice in comparison to wild type mice.
  • eosinophils from IL-5 transgenic mice displayed comparable levels of CD48 compared to wild type mice ( FIG. 6G ). Therefore, in vivo up-regulation of CD48 expression on mouse eosinophils, like in vitro up-regulation of CD48 on human eosinophils, is induced by IL-3 but not IL-5 in vivo.
  • CD48 is Up-Regulated on Murine Eosinophils in Experimental Asthma and Experimental Allergic Peritonitis
  • IL-3 is responsible for the elevated expression of CD48 observed in murine experimental asthma
  • neutralizing antibodies to IL-3 or isotype matched control antibodies were administered to OVA challenged mice.
  • Neutralization of IL-3 in OVA-challenged mice resulted in a 33% decrease (p ⁇ 0.05) in CD48 expression by BALF eosinophils ( FIG. 8A ), decreased the number of infiltrating BALF eosinophils ( FIG. 8B ) and attenuated lung inflammation ( FIG. 8C ) while an isotype-matched control antibody had no effect.
  • CD48 is upregulated in allergic-eosinophilic airway inflammation raised the possibility that this type of inflammation is dependent on CD48 and its ligands. Consequently, the inventors used specific neutralizing antibodies for CD48, CD2 and 2B4 to investigate their roles in this experimental regime ( FIG. 10A-F ).
  • mice treated with anti-CD2 or anti-2B4 mAb exhibited only a ⁇ 40-50% decrease in the BALF cytokine profile or had no effect, respectively.
  • all of the aforementioned effects were specific since mice that were treated with control antibodies displayed equivalent cytokine levels to OVA-challenged mice.
  • the aforementioned antibodies were also analyzed by us to role out the possibility that they may deplete targeted cells in vivo. As shown by FIG. 10G , administration of anti-CD48, anti-CD2 and anti-2B4 Abs did not alter splenic and peripheral blood cellular composition or numbers.
  • FIG. 11A-D lung histology followed by quantitative analysis was performed to assess the effects of CD48 and its ligands on several parameters of lung inflammation.
  • OVA challenged mice displayed evident perivascular and peribronchial eosinophilic inflammation, epithelial damage and airway muscle thickening.
  • Anti-CD48 treated mice had a striking reduction in alveolar space, lung perivascular and peribronchial inflammation and epithelial shedding ( FIG. 11A-D ).
  • This effect was specific to CD48 treatment since anti-CD2 treatment induced a mild inhibitory effect only on the peribronchial inflammatory score, and anti-2B4 treatment seemed to enhance lung inflammation.
  • control antibodies did not alter these features.
  • the thickness of the peribronchial smooth muscle layer was significantly greater in OVA-challenged mice than in saline-challenged mice.
  • Anti-CD48 mAb-treated mice displayed significantly less smooth muscle thickening ( FIG. 12C ).
  • Anti-CD2-treated mice exhibited a minor reduction, while anti-2B4 and control antibodies had no effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US14/566,737 2006-02-14 2014-12-11 Novel therapeutic target and diagnostic marker for asthma and related conditions Abandoned US20150098952A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/566,737 US20150098952A1 (en) 2006-02-14 2014-12-11 Novel therapeutic target and diagnostic marker for asthma and related conditions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77288306P 2006-02-14 2006-02-14
US11/705,829 US8409565B2 (en) 2006-02-14 2007-02-14 Therapeutic target and diagnostic marker for asthma and related conditions
US13/780,994 US20130177575A1 (en) 2006-02-14 2013-02-28 Novel therapeutic target and diagnostic marker for asthma and related conditions
US14/566,737 US20150098952A1 (en) 2006-02-14 2014-12-11 Novel therapeutic target and diagnostic marker for asthma and related conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/780,994 Continuation US20130177575A1 (en) 2006-02-14 2013-02-28 Novel therapeutic target and diagnostic marker for asthma and related conditions

Publications (1)

Publication Number Publication Date
US20150098952A1 true US20150098952A1 (en) 2015-04-09

Family

ID=38479203

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/705,829 Expired - Fee Related US8409565B2 (en) 2006-02-14 2007-02-14 Therapeutic target and diagnostic marker for asthma and related conditions
US13/780,994 Abandoned US20130177575A1 (en) 2006-02-14 2013-02-28 Novel therapeutic target and diagnostic marker for asthma and related conditions
US14/566,737 Abandoned US20150098952A1 (en) 2006-02-14 2014-12-11 Novel therapeutic target and diagnostic marker for asthma and related conditions

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11/705,829 Expired - Fee Related US8409565B2 (en) 2006-02-14 2007-02-14 Therapeutic target and diagnostic marker for asthma and related conditions
US13/780,994 Abandoned US20130177575A1 (en) 2006-02-14 2013-02-28 Novel therapeutic target and diagnostic marker for asthma and related conditions

Country Status (1)

Country Link
US (3) US8409565B2 (en,)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533039B2 (en) 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
AR083044A1 (es) * 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
CA2840522A1 (en) 2011-06-23 2012-12-27 Children's Hospital Medical Center Molecular diagnostic panel of eosinophilic gastrointestinal disorders
EP4059570A1 (en) 2016-01-13 2022-09-21 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
WO2019204580A1 (en) 2018-04-20 2019-10-24 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
CN110376389A (zh) * 2019-08-28 2019-10-25 重庆三峡医药高等专科学校 一种检测嗜酸性粒细胞碱性蛋白的胶体金试纸条

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO933597A0 (en) * 1997-09-22 1997-10-09 Crc For Biopharmaceutical Research Pty Ltd Diagnostic method
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
WO2005094886A1 (ja) * 2004-03-31 2005-10-13 Kirin Beer Kabushiki Kaisha Gpiアンカー蛋白質アゴニストによる調節性t細胞分化誘導・増殖方法およびそのための医薬組成物

Also Published As

Publication number Publication date
US8409565B2 (en) 2013-04-02
US20130177575A1 (en) 2013-07-11
US20070212353A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
US20150098952A1 (en) Novel therapeutic target and diagnostic marker for asthma and related conditions
Mariotte et al. A mouse model of MSU-induced acute inflammation in vivo suggests imiquimod-dependent targeting of Il-1β as relevant therapy for gout patients
JP6999417B2 (ja) Ｉｂｄにおける治療標的及びバイオマーカー
US20230374145A1 (en) Treatment And Inhibition Of Inflammatory Lung Diseases In Patients Having Risk Alleles In The Genes Encoding IL33 And IL1RL1
CN104718222A (zh) 炎症促发多肽及其用途
US7919248B2 (en) Methods for the modulation of IL-13
Emancipator Prospects and perspectives on IgA nephropathy from animal models
WO2016031996A1 (ja) 関節炎の予防·治療剤、検査キット、並びに関節炎予防·治療薬のスクリーニング方法
CN112654397B (zh) 用于治疗哮喘和过敏性疾病的方法和组合物
US20250215074A1 (en) Methods for reducing respiratory infections
JP2023055804A (ja) Ｃａｒｄ１４を用いた治療、診断およびスクリーニング
US20230096203A1 (en) Methods for detecting food allergies
HK40069286A (en) Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
EP4274565A1 (en) Soy isoflavones for asthma prevention
WO2016176501A1 (en) Methods of local induction of t regulatory cells
Palomares et al. Innate and adaptive immune responses in asthma
Raundhal Characterization of Immune Response in Corticosteroid-refractory Severe Asthma in Humans and Mice

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHILDREN'S HOSPITAL MEDICAL CENTER, D/B/A/ CINCINN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROTHENBERG, MARC E.;REEL/FRAME:034821/0876

Effective date: 20141120

Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEVI-SCHAFFER, FRANCESCA;BACHELET, IDO;MUNITZ, ARIEL;SIGNING DATES FROM 20141123 TO 20141222;REEL/FRAME:034822/0055

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION